Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 0.98 |
| ▸ | GNA15 | P30679 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518942 | 1.00 | FFAR1 (0.98) | FFAR1GNA15 | |
| SCHEMBL29367214 | 0.99 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL13118205 | 0.99 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL3553422 | 0.99 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL12194429 | 0.99 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL18884086 | 0.93 | FFAR1 (0.88) | FFAR1GNA15 | |
| SCHEMBL13118209 | 0.93 | FFAR1 (0.88) | FFAR1GNA15 | |
| SCHEMBL12191648 | 0.92 | FFAR1 (0.86) | FFAR1GNA15 | |
| SCHEMBL3518944 | 0.91 | FFAR1 (0.84) | FFAR1GNA15 | |
| SCHEMBL5297906 | 0.91 | FFAR1 (0.84) | FFAR1GNA15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737809-A4 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1737809-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005086661-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2005-09-22 | — | — | WO | disclosed |